-
公开(公告)号：US20100266673A1
公开(公告)日：2010-10-21
申请号：US12302004
申请日：2007-05-21
Applicant: Stephen P. L. Cary , Elizabeth M. Boon , Jonathan A. Winger , Michael A. Marletta
Inventor： Stephen P. L. Cary , Elizabeth M. Boon , Jonathan A. Winger , Michael A. Marletta
IPC: A61K38/16 , A61K9/127 , A61P9/00 , A61P9/12 , A61P13/12 , C07K14/00 , C07H21/04 , C12N15/63 , C12N5/10 , C12P21/00
CPC classification number: C07K14/47 , A61K38/00 , C07K14/195 , C07K14/33 , C07K14/435 , C07K14/43545 , C07K14/43563 , C07K14/43581 , Y02A50/469 , Y02A50/471 , Y02A50/478 , Y10T436/102499
Abstract: H-NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas NO delivery. The engineered H-NOX proteins comprise mutations that impart altered NO or 02 ligand-binding relative to the corresponding wild-type H-NOX domain, and are operative as physiologically compatible mammalian blood NO gas carriers. The invention also provides pharmaceutical compositions, kits, and methods that use wild-type or mutant H-NOX proteins for the treatment of any condition for which delivery of NO is beneficial.
Abstract translation: H-NOX蛋白被突变以表现出改善的或最佳的动力学和热力学性质用于血气NO递送。 工程化的H-NOX蛋白质包含相对于相应的野生型H-NOX结构域赋予改变的NO或O 2配体结合的突变，并且作为生理上相容的哺乳动物血液NO气体载体起作用。 本发明还提供了使用野生型或突变型H-NOX蛋白质用于治疗NO的递送有益的任何病症的药物组合物，试剂盒和方法。
-
公开(公告)号：US07202037B2
公开(公告)日：2007-04-10
申请号：US10641884
申请日：2003-08-14
Applicant: Jacqueline K. Barton , Elizabeth M. Boon , Shana O. Kelley , Michael G. Hill
Inventor： Jacqueline K. Barton , Elizabeth M. Boon , Shana O. Kelley , Michael G. Hill
CPC classification number: C12Q1/6827 , B82Y30/00 , C12Q1/6825 , C12Q1/6837 , C12Q2565/607 , C12Q2563/113 , C12Q2563/173
Abstract: Compositions and methods for electrochemical detection and localization of genetic point mutations, common DNA lesions and other base-stacking perturbations within oligonucleotide duplexes adsorbed onto electrodes and their use in biosensing technologies are described. An intercalative, redox-active moiety (such as an intercalator or nucleic acid-binding protein) is adhered and/or crosslinked to immobilized DNA duplexes at different separations from an electrode and probed electrochemically in the presence or absence of a non-intercalative, redox-active moiety. Interruptions in DNA-mediated electron-transfer caused by base-stacking perturbations, such as mutations or binding of a protein to its recognition site are reflected in a difference in electrical current, charge and/or potential.
Abstract translation: 描述了吸附在电极上的寡核苷酸双链体内的遗传点突变，常见DNA病变和其他碱基堆叠扰动的电化学检测和定位及其在生物传感技术中的应用的组合物和方法。 插入的氧化还原活性部分（例如嵌入剂或核酸结合蛋白）在与电极的不同分离处固定和/或交联固定的DNA双链体并且在存在或不存在非插入式氧化还原的情况下电化学研究 活性部分。 由碱基堆叠扰动导致的DNA介导的电子转移的中断，例如蛋白质与其识别位点的突变或结合反映在电流，电荷和/或电位的差异中。
-
公开(公告)号：US08404632B2
公开(公告)日：2013-03-26
申请号：US12302004
申请日：2007-05-21
Applicant: Stephen P. L. Cary , Elizabeth M. Boon , Jonathan A. Winger , Michael A. Marletta
Inventor： Stephen P. L. Cary , Elizabeth M. Boon , Jonathan A. Winger , Michael A. Marletta
IPC: C07K14/00
CPC classification number: C07K14/47 , A61K38/00 , C07K14/195 , C07K14/33 , C07K14/435 , C07K14/43545 , C07K14/43563 , C07K14/43581 , Y02A50/469 , Y02A50/471 , Y02A50/478 , Y10T436/102499
Abstract: H-NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas NO delivery. The engineered H-NOX proteins comprise mutations that impart altered NO or O2 ligand-binding relative to the corresponding wild-type H-NOX domain, and are operative as physiologically compatible mammalian blood NO gas carriers. The invention also provides pharmaceutical compositions, kits, and methods that use wild-type or mutant H-NOX proteins for the treatment of any condition for which delivery of NO is beneficial.
Abstract translation: H-NOX蛋白被突变以表现出改善的或最佳的动力学和热力学性质用于血气NO递送。 工程化的H-NOX蛋白质包含相对于相应的野生型H-NOX结构域赋予改变的NO或O 2配体结合的突变，并且作为生理上相容的哺乳动物血液NO气体载体起作用。 本发明还提供了使用野生型或突变型H-NOX蛋白质用于治疗NO的递送有益的任何病症的药物组合物，试剂盒和方法。
-
Patent Agency Ranking
公开(公告)号：US20100285104A1
公开(公告)日：2010-11-11
申请号：US12302002
申请日：2007-05-21
Applicant: Stephen P. L. Cary , Elizabeth M. Boon , Emily Weinert , Jonathan A. Winger , Michael A. Marletta
Inventor： Stephen P. L. Cary , Elizabeth M. Boon , Emily Weinert , Jonathan A. Winger , Michael A. Marletta
IPC: A61K9/127 , C12P21/06 , C12N5/10 , C12N5/02 , C12N15/63 , G01N31/00 , A61K38/00 , C07K14/435 , C07H21/04 , C07K14/195
CPC classification number: C07K14/47 , A61K38/00 , C07K14/195 , C07K14/33 , C07K14/435 , C07K14/43545 , C07K14/43563 , C07K14/43581 , Y02A50/469 , Y02A50/471 , Y02A50/478 , Y10T436/102499
Abstract: H-NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas O2 delivery. The engineered H-NOX proteins comprise mutations that impart altered O2 or NO ligand-binding relative to the corresponding wild-type H-NOX domain, and are operative as physiologically compatible mammalian blood O2 gas carriers. The invention also provides pharmaceutical compositions, kits, and methods that use wild-type or mutant H-NOX proteins for the treatment of any condition for which delivery of O2 is beneficial.
Abstract translation: H-NOX蛋白被突变以表现出改善的或最佳的动力学和热力学性质用于血液中氧气输送。 工程化的H-NOX蛋白质包含相对于相应的野生型H-NOX结构域赋予改变的O 2或NO配体结合的突变，并且作为生理上相容的哺乳动物血液氧气载体起作用。 本发明还提供了使用野生型或突变型H-NOX蛋白质治疗任何有利于O 2递送的条件的药物组合物，试剂盒和方法。
-
公开(公告)号：US20150266931A1
公开(公告)日：2015-09-24
申请号：US14490597
申请日：2014-09-18
Applicant: STEPHEN P. L. CARY , ELIZABETH M. BOON , JONATHAN A. WINGER , MICHAEL A. MARLETTA
Inventor： STEPHEN P. L. CARY , ELIZABETH M. BOON , JONATHAN A. WINGER , MICHAEL A. MARLETTA
IPC: C07K14/195 , C07K14/33 , C07K14/435
CPC classification number: C07K14/47 , A61K38/00 , C07K14/195 , C07K14/33 , C07K14/435 , C07K14/43545 , C07K14/43563 , C07K14/43581 , Y02A50/469 , Y02A50/471 , Y02A50/478 , Y10T436/102499
Abstract: H-NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas NO delivery. The engineered H-NOX proteins comprise mutations that impart altered NO or O2 ligand-binding relative to the corresponding wild-type H-NOX domain, and are operative as physiologically compatible mammalian blood NO gas carriers. The invention also provides pharmaceutical compositions, kits, and methods that use wild-type or mutant H-NOX proteins for the treatment of any condition for which delivery of NO is beneficial.
Abstract translation: H-NOX蛋白被突变以表现出改善的或最佳的动力学和热力学性质用于血气NO递送。 工程化的H-NOX蛋白质包含相对于相应的野生型H-NOX结构域赋予改变的NO或O 2配体结合的突变，并且作为生理上相容的哺乳动物血液NO气体载体起作用。 本发明还提供了使用野生型或突变型H-NOX蛋白质用于治疗NO的递送有益的任何病症的药物组合物，试剂盒和方法。
-
6.发明申请Modified Diguanylate Cyclase-Phosphodiesterase and Method for Enzymatic Production of Cyclic-diGMP 审中-公开改良的二环戊二烯基环化酶 - 磷酸二酯酶和循环diGMP酶促生产方法公开(公告)号：US20140170689A1
公开(公告)日：2014-06-19
申请号：US14104488
申请日：2013-12-12
Applicant: Natasha M. NESBITT , Roger A. JOHNSON , Elizabeth M. BOON
Inventor： Natasha M. NESBITT , Roger A. JOHNSON , Elizabeth M. BOON
CPC classification number: C12N9/18 , C12N9/1241 , C12P19/36 , C12Q1/44 , C12Q1/485 , C12Y207/07065 , G01N2333/91245 , G01N2333/916
Abstract: The present invention provides a recombinant polypeptide comprising a first portion and a second portion, wherein the sequence of the first portion is fully identical to amino acids 1 to 248 of the sequence set forth as SEQ ID NO:1 and the sequence of the second portion is other than amino acids 249 to 511 of the sequence set forth as SEQ ID NO:1.
Abstract translation: 本发明提供了包含第一部分和第二部分的重组多肽，其中第一部分的序列与SEQ ID NO：1所示序列的氨基酸1至248完全相同，第二部分的序列 不同于SEQ ID NO：1所示序列的氨基酸249至511。
-
公开(公告)号：US08404631B2
公开(公告)日：2013-03-26
申请号：US12302002
申请日：2007-05-21
Applicant: Stephen P. L. Cary , Elizabeth M. Boon , Emily Weinert , Jonathan A. Winger , Michael A. Marletta
Inventor： Stephen P. L. Cary , Elizabeth M. Boon , Emily Weinert , Jonathan A. Winger , Michael A. Marletta
IPC: C07K14/00
CPC classification number: C07K14/47 , A61K38/00 , C07K14/195 , C07K14/33 , C07K14/435 , C07K14/43545 , C07K14/43563 , C07K14/43581 , Y02A50/469 , Y02A50/471 , Y02A50/478 , Y10T436/102499
Abstract: H-NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas O2 delivery. The engineered H-NOX proteins comprise mutations that impart altered O2 or NO ligand-binding relative to the corresponding wild-type H-NOX domain, and are operative as physiologically compatible mammalian blood O2 gas carriers. The invention also provides pharmaceutical compositions, kits, and methods that use wild-type or mutant H-NOX proteins for the treatment of any condition for which delivery of O2 is beneficial.
Abstract translation: H-NOX蛋白被突变以表现出改善的或最佳的动力学和热力学性质用于血液中氧气输送。 工程化的H-NOX蛋白质包含相对于相应的野生型H-NOX结构域赋予改变的O 2或NO配体结合的突变，并且作为生理上相容的哺乳动物血液氧气载体起作用。 本发明还提供了使用野生型或突变型H-NOX蛋白质治疗任何有利于O 2递送的条件的药物组合物，试剂盒和方法。
-
公开(公告)号：US06649350B2
公开(公告)日：2003-11-18
申请号：US09953242
申请日：2001-09-13
Applicant: Jacqueline K. Barton , Elizabeth M. Boon , Shana O. Kelley , Michael G. Hill
Inventor： Jacqueline K. Barton , Elizabeth M. Boon , Shana O. Kelley , Michael G. Hill
IPC: C12Q168
CPC classification number: C12Q1/6827 , B82Y30/00 , C12Q1/6825 , C12Q1/6837 , C12Q2565/607 , C12Q2563/113 , C12Q2563/173
Abstract: Compositions and methods for electrochemical detection and localization of genetic point mutations, common DNA lesions and other base-stacking perturbations within oligonucleotide duplexes adsorbed onto electrodes and their use in biosensing technologies are described. An intercalative, redox-active moiety (such as an intercalator or nucleic acid-binding protein) is adhered and/or crosslinked to immobilized DNA duplexes at different separations from an electrode and probed electrochemically in the presence or absence of a non-intercalative, redox-active moiety. Interruptions in DNA-mediated electron-transfer caused by base-stacking perturbations, such as mutations or binding of a protein to its recognition site are reflected in a difference in electrical current, charge and/or potential.
-
-
-
-
-
-
-
Search Results
8
records
(took 0.02 seconds)
